Company Filing History:
Years Active: 2005-2008
Title: Valerie Polard-Housset: Innovator in Signal Transduction Pathways
Introduction
Valerie Polard-Housset, an accomplished inventor based in Jouy en Josas, France, has made significant contributions to the field of biochemistry through her innovative research. With a focus on the MEKK signal transduction pathway, she holds two patents that aim to further our understanding of cellular signaling mechanisms.
Latest Patents
Polard-Housset's latest patents include groundbreaking work on the MEKK1-interacting FHA protein 1 (MIF1). These inventions relate to a novel protein and its encoding gene, which have potential diagnostic and therapeutic applications. The patents outline methods for screening agonists or antagonists of MIF1, with a particular focus on its interaction with MEKK. The MIF1 protein and gene can be leveraged in screening assays, contributing valuable insights into modulators of the MEKK signaling pathway. Furthermore, MIF1 can be utilized in gene therapy applications, demonstrating the potential to deliver the MIF1 gene to cells for various testing scenarios.
Career Highlights
Valerie Polard-Housset is a notable employee at Aventis Pharma S.A., where her research significantly impacts pharmaceutical development. Her role within the company showcases her commitment to advancing therapeutic solutions that can benefit patients worldwide.
Collaborations
Throughout her career, Polard-Housset has collaborated with esteemed colleagues, including Christophe Marcireau and Marie-Christine Multon. These partnerships reflect a collaborative spirit that drives innovation and enhances research outcomes in the field.
Conclusion
Valerie Polard-Housset stands out as a prominent inventor in biochemistry, with valuable patents that enhance our understanding of cellular processes. Her work at Aventis Pharma S.A., coupled with effective collaborations, establishes her as a key figure in the landscape of medical innovation.